FindMyKOL

Rohan Samson, MD

Basic profile

UofL Health

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionLouisville, KY · SoutheastSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLFindMyKOL type: NationalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Rohan Samson is a Cardiology physician affiliated with UofL Health. OpenAlex indexes 76 publications with 829 citations (h-index 14).

Overview

Scholarship

indexed output and impact (OpenAlex)
76publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

829citations

Citations across these publications.

14h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
40companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

40 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Merck & Co.
    Program year20251 paymentResearch
    $180,119
  • E.R. Squibb & Sons, L.L.C.
    Program year202553 payments
    $77,845
  • Boston Scientific Corporation
    Program year202513 payments
    $481
All 86 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    71.1%
    Beta blocker18.7%
    Metoprolol Succinate72%Carvedilol28%
    Part D≥55 patients
    Loop diuretic14%
    Bumetanide55%Furosemide33%Torsemide12%
    Part D<11 patients

    + 11 more classes in this area

  • Metabolism & gastrointestinal

    17%
    Potassium supplement8%
    Potassium Chloride81%Klor-Con M2019%
    Part D<11 patients
    SGLT2 inhibitor4.5%
    Jardiance58%Farxiga42%
    Part D<11 patients

    + 3 more classes in this area

  • Blood & clotting

    6.3%
    Factor Xa inhibitor3.5%
    Eliquis100%
    Part D≥15 patients
    P2Y12 inhibitor2.8%
    Clopidogrel100%
    Part D≥12 patients
Where care is delivered (Part B)89.3% facility · 10.7% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”